News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Elan Corporation PLC (ELN) Raises $381 Million in Sale of 76% of Alkermes plc (ALKS)



3/13/2012 10:51:54 AM

DUBLIN--(BUSINESS WIRE)--Elan Corporation, plc (NYSE: ELN) today raised approximately $381 million in net proceeds from the sale of 76% (24.15 million ordinary shares) of its shareholding in Alkermes plc (NASDAQ: ALKS), net of underwriter fees. These proceeds further strengthen Elan’s cash balances and capital structure.

In September 2011, when Elan combined its Elan Drug Technology (EDT) business with Alkermes Inc, Elan received $500 million in cash and 31.9 million ordinary shares in the newly created Alkermes plc. Following today's transaction, Elan continues to own 7.75 million Alkermes plc ordinary shares, which are subject to legal and contractual transfer restrictions.

For additional details on the transaction please refer to Alkermes plc announcement from earlier today.

About Elan

Elan is a neuroscience focused biotechnology company committed to making a difference in the lives of patients and their families by dedicating itself to bringing innovations in science to fill significant unmet medical needs that continue to exist around the world. For additional information about Elan, please visit http://www.elan.com.

SOURCE: Elan Corporation, plc:

Contacts

Media:

Niamh Lyons

Tel: + 353-1-709-4176

or

Investor Relations:

Chris Burns

Tel: + 800-252-3526

or

David Marshall

Tel: + 353 -1-709-4444


Read at BioSpace.com
Read at News Release
Read at RTT News
Read at Pharma Times [Free Reg Req'd]
Read at CBS News


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES